Oscillo icon
A Vast Unmet Need

Market Opportunity

Despite billions spent on research, there is still no cure for Alzheimer’s Disease (AD).

Since 1995, $42.5B has been invested in more than 1,000 trials.

Oscillo icon
A Digital Revolution in Medicine

The Digital Therapeutics Market

Prescription Digital Therapeutics (PTDs), a relatively new class of medicine recognized by the FDA, are gaining wide acceptance across the medical spectrum. Irritable bowel syndrome, eczema, respiratory disease and diabetes are just a few of the indications doctors are treating with tech.

By 2029, the PTD market is projected to be valued at $26.3B.

It’s easy to see why this market is booming. Most PTDs—like ours—offer the convenience of in-home use. Many are delivered via technology that patients already own—e.g., mobile phones or tablets. Treatment can be highly individualized, and data capture allows doctors to quickly know how well it’s working. Some even include a game-like experience, which is great for patient compliance.

Oscillo icon

The Economic Impact of Alzheimer’s

Since 2000, deaths from Alzheimer’s disease have increased by 89%.

In the United States, without a means of prevention or a cure, this disease will contribute cumulative costs of almost $20 trillion to Medicare and Medicaid spending by 2050.

In 2022, the total national cost of caring for people living with Alzheimer’s and other dementias was estimated at $321 billion.

In 2021, unpaid dementia caregiving was estimated to be 16 billion hours, valued at $271.6 billion.

Oscillo icon

News & Publications

Go to Top